MUL1 and Cerebral ischemia: Furthermore, GCK treatment could decrease the binding affinity of Mul1 and Mfn2, inhibit Mul1/Mfn2-mediated ubiquitination and degradation, and increase the protein level of Mfn2 in cerebral ischemia-reperfusion injury.